The entire world is looking up to India in the backdrop of the success of its COVID-19 vaccination drive, Prime Minister Narendra Modi said on Saturday as he lauded vaccine manufacturers for playing a "big role" in the success story of the country.
Modi made the remarks during his meeting with Indian COVID-19 vaccine manufacturers who said his leadership was a key factor in India being able to administer 100 crore doses of the jabs in just about nine months.
The domestic vaccine manufacturers appreciated the vision and dynamic leadership of the prime minister in providing continuous guidance and support towards the development of the vaccines, a statement issued by the Prime Minister's Office (PMO) said.
They also praised the never-seen-before collaboration between the government and the industry, and applauded the regulatory reforms, simplified procedures, timely approvals, and forthcoming and supportive nature of the government throughout this endeavour, the PMO said.
The vaccine manufacturers noted that had the country been following old norms, there would have been a considerable delay and "we would not have been able to reach the vaccination level that we have attained till now," the statement said.
Prime Minister Modi praised the efforts of the vaccine manufacturers, which has resulted in the country crossing the milestone of 100 crore vaccinations, and said that they have played a big role in the success story of India.
He appreciated their hard work and confidence given by them during the pandemic, the PMO said.
The prime minister exhorted that the country needs to institutionalise the best practises learnt during the last one-and-a-half years, and said that this is an opportunity to modify our practises, in tune with the global standards.
He said that the entire world is looking up to India in the backdrop of the success of the vaccination drive.
Modi also said that the vaccine manufacturers should continuously work together to be ready to face future challenges.
The interaction was attended by Cyrus Poonawalla and Adar Poonawalla, Serum Institute of India; Dr. Krishna Ella and Suchitra Ella, Bharat Biotech International Ltd; Pankaj Patel and Shervil Patel, Zydus Cadila; Mahima Datla and Narender Mantela, Biological E. Ltd; Sanjay Singh and Satish Ramanlal Mehta, Gennova Biopharmaceuticals Ltd; Satish Reddy and Deepak Sapra, Dr. Reddy's Lab; and Rajesh Jain and Harshit Jain, Panacea Biotec Ltd.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)